Biologics are an exciting new world of medicine. But the EMA's new guidelines should put patient safety first by requiring biosimilars to be held to the same safety and standards as the original drug.
Read Whole Story
Get top stories and blog posts emailed to me each day. Newsletters may offer personalized content or advertisements. Learn more.